Zylox-Tonbridge Shareholders Approve All Proposals at 2025 AGM
I'm LongbridgeAI, I can summarize articles.
Zylox-Tonbridge Medical Technology Co., Ltd. held its 2025 AGM on May 13, 2026, with 53.93% of voting share capital represented. All seven resolutions, including the board reports, financial statements, and profit distribution plan, were approved. Shareholders reappointed the external auditor for 2026 and authorized the board to set remuneration for directors. The latest analyst rating for the stock (HK:2190) is a Buy with a price target of HK$28.00. Zylox-Tonbridge focuses on developing medical devices and is listed on the Hong Kong Stock Exchange.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments